AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30692875
Drug: High-Dose Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Remifentanil
Trial: 30692875
Drug: Low-Dose Remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Remifentanil
Trial: 26427789
Drug: Topical Matricaria
RxNorm normalized name: Matricaria chamomilla flowering top oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Matricaria recutita L (chamomile) oil
Trial: 26123824
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen trometamol 25 mg plus tramadol hydrochloride 75 mg
Trial: 26123824
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen trometamol 12.5 mg plus tramadol hydrochloride 37.5 mg
Trial: 9882082
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen trometamol 25 mg
Trial: 26123824
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride 75 mg
Trial: 26123824
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride 37.5 mg
Trial: 23853029
Drug: AFQ056 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFQ056 200 mg daily
Trial: 23853029
Drug: AFQ056 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFQ056 50 mg daily
Trial: 16585866
Drug: Hydrocodone/acetaminophen 7.5/750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/acetaminophen 7.5/750 mg
Trial: 11556458
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac tromethamine
Trial: 9628270
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin administered i.v. by continuous infusion for 7 days, followed by daily s.c. injections for 6 months. Intravenous insulin infusions were repeated every 12 months.
Trial: 2736431
Drug: Azelastine 8.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 8.8 mg
Trial: 2904931
Drug: Azelastine 17.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 17.6 mg
Trial: 30597523
Drug: Weight reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight reduction and IVF treatment (n = 160)
Trial: 26432647
Drug: remedē System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remedē System therapy initiated at 1 month after implantation
Trial: 26432647
Drug: remedē System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remedē System therapy
Trial: 21071527
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula with continuous flow at 2 L/min
Trial: 21071527
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula with oxygen-conserving device at 2 L/min
Trial: 21071527
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula with portable oxygen concentrator at 2 L/min
Trial: 19864035
Drug: Transarterial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transarterial infusion chemotherapy (TAI) with zinostatin stimalamer
Trial: 11824325
Drug: Combined radio-chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radio-chemotherapy (cisplatin 75 mg/m2 d1, etoposide 120 mg/m2 d1-3, Ifosfamid 1.5 mg/m2 d1-4, 3 cycles)
Trial: 2368889
Drug: Thiopentone 4
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 4 mg.kg‐1
Trial: 2466389
Drug: Diazepam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.15 mg kg‐1 orally 2 hours before operation (Group III)
Trial: 2466389
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet 2 hours before operation (Group IV)
Trial: 26882102
Drug: Recombinant Human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant Human Interferon α1b therapy (rHuIFN‐α1b)
Trial: 22889285
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser as an adjunct to mechanical debridement
Trial: 15915010
Drug: Formoterol pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol pMDI (cumulative doses up to 96 microg)
Trial: 15915010
Drug: Formoterol DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol DPI (cumulative doses up to 96 microg)
Trial: 12409652
Drug: gemcitabine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine with or without a farnesyl transferase inhibitor
Trial: 12409652
Drug: histone deacetylase
RxNorm normalized name: Histone deacetylase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: histone deacetylase inhibitor
Trial: 12409652
Drug: 9‐nitrocamptothecin (topoisomerase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9‐nitrocamptothecin (topoisomerase I inhibitor)
Trial: 12409652
Drug: oxaliplatin to
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin to high‐dose 5FU plus leucovorin
Trial: 7589056
Drug: Microemulsion formulation
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microemulsion formulation of cyclosporin at 200 mg
Trial: 7589056
Drug: Microemulsion formulation
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microemulsion formulation of cyclosporin at 800 mg
Trial: 2237853
Drug: 100-150 mg
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100-150 mg acetylsalicylic acid per day for prophylaxis after acute myocardial infarction
Trial: 2237853
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg acetylsalicylic acid for cerebrovascular indications
Trial: 109916
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg disodium cromoglycate (DSCG) inhaled with a spinhaler 30 minutes before exercise
Trial: 109916
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of ketotifen taken orally 3 hours before exercise
Trial: 109916
Drug: Placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder inhaled with a spinhaler
Trial: 31769533
Drug: Gluten (6-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten (6-g gluten protein)
Trial: 28117400
Drug: Phytosterols-enriched low-fat
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterols-enriched low-fat milk (1.5 g phytosterols per day)
Trial: 23702253
Drug: Grape seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape seed extract (GSE) 300 mg/d
Trial: 9272408
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral ketotifen daily
Trial: 9272408
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral ketotifen daily
Trial: 7871077
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg sarmazenil
Trial: 7871077
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg sarmazenil
Trial: 3544792
Drug: verapamil-SR, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil-SR, 240 mg twice daily
Trial: 3544792
Drug: regular formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: regular formulation of verapamil, 120 mg 4 times daily
Trial: 31595482
Drug: Inactivated quadrivalent
RxNorm normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated quadrivalent influenza vaccine (IIV4)
Trial: 26462707
Drug: BMS 914392
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS 914392 (10 mg OD)
Trial: 26462707
Drug: BMS 914392
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS 914392 (10 mg TDS)
Trial: 26462707
Drug: BMS 914392
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS 914392 (20 mg TDS)
Trial: 12243291
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine injection after combined spinal anaesthesia
Trial: 12243291
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine injection after epidural anaesthesia
Trial: 7560628
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg, n = 22)
Trial: 7560628
Drug: Ibopamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (100 mg three times a day, n = 19)
Trial: 2827044
Drug: Diltiazem (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120 mg twice daily)
Trial: 1963183
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Diltiazem + Atenolol)
Trial: 30028922
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO2) therapy
Trial: 21694614
Drug: Mifepristone (300,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (300, 600, or 1200 mg)
Trial: 21694614
Drug: Mifepristone (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (plasma concentrations > 1660 ng/mL)
Trial: 16418022
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block with 0.75% ropivacaine administered before surgery (PRE group)
Trial: 16418022
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block with 0.75% ropivacaine administered after surgery (POST group)
Trial: 10693082
Drug: Environmental exposures
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Environmental exposures to perchlorate (up to 15 micrograms/L)
Trial: 9465587
Drug: EBRT combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT combined with BRTX (mean dose 50.2 +/- 13.2 Gy, dose rate of 0.3-0.4 Gy/hr)
Trial: 9465587
Drug: Standard EBRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard EBRT (mean dose 51.5 +/- 12.4 Gy in 2.0 Gy fractions)
Trial: 3332129
Drug: 10 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 Gy single dose TBI (n = 27)
Trial: 3332129
Drug: 9.2 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.2 Gy single dose TBI (n = 22)
Trial: 3332129
Drug: 9.2 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.2 Gy single dose TBI
Trial: 3332129
Drug: 9.2 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.2 Gy single dose TBI and 10 Gy single dose TBI
Trial: 26669919
Drug: Ixekizumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab treatment
Trial: 24767551
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic paste (metronidazole, ciprofloxacin, and minocycline) (TAP)
Trial: 24767551
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcium hydroxide and 2% chlorhexidine gel (CHP)
Trial: 20056686
Drug: Kaletra tablets
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kaletra tablets (400 mg of lopinavir)
Trial: 20056686
Drug: Lopimune granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopimune granules (400 mg of lopinavir)
Trial: 20056686
Drug: Lopimune paediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopimune paediatric tablets (400 mg of lopinavir)
Trial: 20056686
Drug: Kaletra solution
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kaletra solution with food
Trial: 20056686
Drug: Lopimune formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopimune formulations
Trial: 15630410
Drug: val66met SNP
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: val66met SNP (allele G) in schizophrenia group
Trial: 14738367
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of video and text information
Trial: 10370680
Drug: Interferon-alpha administered
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A)
Trial: 10370680
Drug: Interferon-alpha administered
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B)
Trial: 10370680
Drug: Interferon-alpha administered
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A) in intermediate viral load group
Trial: 10370680
Drug: Interferon-alpha administered
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B) in intermediate viral load group
Trial: 10370680
Drug: Interferon-alpha administered
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A) in genotype 2 patients
Trial: 10370680
Drug: Interferon-alpha administered
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B) in genotype 2 patients
Trial: 8900905
Drug: Cholic acid
RxNorm normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cholic acid (500 mg/day for 4 weeks)
Trial: 8900905
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (500 mg/day for 4 weeks)
Trial: 8900905
Drug: Deoxycholic acid
RxNorm normalized name: Deoxycholic Acid
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deoxycholic acid (500 mg/day for 4 weeks)
Trial: 8900905
Drug: Paromomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin (1 g/day for 2 weeks)
Trial: 1807272
Drug: Inhaled toxic
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled toxic chemicals (phenol <0.0025 ppm, ethyl alcohol <0.5 ppm, formaldehyde <0.2 ppm, chlorine <0.3 ppm, pesticide 2,3-D <0.0034 ppm)
Trial: 25186158
Drug: Automated closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated closed-loop insulin delivery
Trial: 24963110
Drug: Sensor-augmented insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensor-augmented insulin pump therapy (SAP)
Trial: 10613232
Drug: Ultrasound gel
RxNorm normalized name: Ultrasound gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound gel
Trial: 25347723
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication review
Trial: 9498972
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (Azmacort) oral inhaler 4 puffs twice daily (800 microg daily) for 7 days
Trial: 9498972
Drug: IV hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV hydrocortisone (3 microg/kg/min) as a 14-h continuous infusion
Trial: 22373835
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg/d
Trial: 24773166
Drug: Sertraline 200
RxNorm normalized name: sertraline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 200 mg/d
Trial: 26991958
Drug: Double-dorsal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dorsal injection
Trial: 26991958
Drug: Single-volar injection
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-volar injection
Trial: 22863660
Drug: CYD-TDV (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYD-TDV (3 injections at months 0, 6, and 12)
Trial: 22863660
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 injections at months 0 and 6) or pneumococcal polysaccharide vaccine (month 12)
Trial: 22863660
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo or pneumococcal polysaccharide vaccine)
Trial: 18775200
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg/d) with extended-release oxybutynin (10 mg/d)
Trial: 18775200
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg/d) alone (Control)
Trial: 11450709
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1 g/day)
Trial: 2896581
Drug: HRP112 (depot‐medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRP112 (depot‐medroxyprogesterone acetate, 25mg and estradiol cypionate, 5 mg)
Trial: 2692962
Drug: HRP102 (norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRP102 (norethisterone enantate, 50 mg and estradiol valerate, 5 mg)
Trial: 31954199
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT) - 300 kcal
Trial: 30659702
Drug: Weekly prompted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly prompted BP self-monitoring and healthy behavior text messages
Trial: 25559659
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 1,200 mg starting two days before the operation, in addition to isonitrogenous and isocaloric total parenteral nutrition.
Trial: 23321948
Drug: Tagged vaginal
RxNorm normalized name: ALLERGENIC EXTRACT, TAG ALDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tagged vaginal gel (4 mL of tenofovir placebo gel with 15 mg 2‐pentyl acetate)
Trial: 23321948
Drug: Tagged condom
RxNorm normalized name: ALLERGENIC EXTRACT, TAG ALDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tagged condom (with 15 mg 2‐butyl acetate)
Trial: 19526810
Drug: Point injection
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point injection of red-sage-root (Danshen) in 5 ml normal saline, 2.5 ml per point, 3 times a week for 6 months
Trial: 24520783
Drug: Routine Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Western medicine (Control)
Trial: 9504446
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg/diltiazem ER 120 mg (E5/D120)
Trial: 9504446
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg/diltiazem ER 180 mg (E5/D180)
Trial: 9504446
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of enalapril/diltiazem ER (E/D)
Trial: 8002149
Drug: Itraconazole, 100
RxNorm normalized name: Itraconazole, 100 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole, 100 mg daily for 6 weeks
Trial: 8002149
Drug: Griseofulvin, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin, 500 mg daily for 6 weeks
Trial: 3400564
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg three times a day in 10 patients and four times a day in 9 patients)
Trial: 3400564
Drug: Digoxin (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.125 mg/day in 2 patients and 0.250 mg/day in 17 patients)